One of the barriers to creating new therapies for pediatric low grade gliomas is the lack of models for finding new drugs.
A “mouse model” does not exist.
The various genetic mutations are not represented in the models that do exist.
Medical researchers do not understand why some low grade gliomas recur, causing the patient to suffer through multiple lines of therapy, while a lucky few patients’ tumors stop growing after one line of treatment.
Why low grade gliomas occur is unknown.
Imagine An Answer’s research will address these questions and speed the development of new drugs for patients with low grade glioma.
Imagine An Answer has partnered with a Johns Hopkins University lab operated by Dr. Eric Rabbe, MD, P.h.D. to focus on finding a cure for pediatric low grade gliomas (LGG’s). This Phase I research focused on:
- Identification of a gene called mTOR that is activated in the brain tumors of patients whose LGG has relapsed. This is key because identification of this gene enables Dr. Raabe and his team to zero in on a specific gene that signals the reappearance of LGG
- Testing of a drug called sapanisertib, which is a so-called mTOR “inhibitor” that prevents the activation of the mTOR gene
- Determination of whether sapanisertib can work together with chemotherapy to enhance the killing of LGG cells
- Testing of another drug called trametinib, which is currently in clinical trials for LGG, to assess whether this drug can work with chemotherapy or sapanisertib to kill LGG cells